Sandoz Slams ‘Desperate’ J&J Attempt To Block US Private-Label Stelara Rival

Provides Update On Expectations For Samsung Bioepis-Partnered Pyzchiva Biosimilar

Sandoz CEO Richard Saynor has spoken of his frustration at a lawsuit from J&J seeking to prevent the launch of a private-label ustekinumab biosimilar in the US, which he described as “the desperate actions of an originator trying to protect its market.”

J&J is seeking to block a private-label ustekinumab biosimilar (Shutterstock)

Reacting to a recently-filed lawsuit from Johnson & Johnson that is seeking to stop partners Samsung Bioepis and Sandoz from introducing a private-label ustekinumab biosimilar rival to Stelara in the US, Sandoz CEO Richard Saynor has spoken of his frustration at what he called “the desperate actions of an originator trying to, I guess, protect its market for as long as practically possible.”

Shortly after Sandoz announced its US launch of the Pyzchiva (ustekinumab-ttwe) biosimilar developed by Samsung Bioepis,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

Reshaped Xbrane Allies With OneSource For Commercial Biosimilar Manufacturing

 
• By 

Xbrane Biopharma is partnering with India’s OneSource Specialty Pharma to manufacture its biosimilars, including its much-delayed ranibizumab product Ximluci. The move follows a SEK240m funding round and strategic refocus on commercialization after divesting key R&D assets to Alvotech.

Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks

 
• By 

Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.

Stelara Biosimilar Sees Stada’s Specialty Sales Start Strong In Q1

 
• By 

Stada’s Specialty division was boosted by the firm’s launch last year of a European Stelara biosimilar, even as generics growth remained muted in Q1.

Formycon Snatches Brazilian Approval For Lucentis Biosimilar

 

Formycon is preparing to start a new era – entering Latin America with its ranibizumab biosimilar, which is expected to be a “good contributor” to the firm’s finances.

More from Policy & Regulation

UK-EU Deal ‘Must Include Medicines, Not Just Sausages,’ Urges Medicines UK

 

The UK struck three international agreements in May, but two of them failed to include medicines or provide any benefits for the pharmaceutical sector. Medicines UK warned that protecting medicine supplies should be of the same importance as defense.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Trump-Trimmed FDA Finally Releases A Batch Of PSGs – Back To Business As Usual?

 

After half a year of silence, the US FDA has published 48 product-specific guidances for generic development. With critical staff laid off, will the health agency stick to its updated PSG publishing schedule?